Replies to post #169 on Fate Therapeutics Inc (FATE)

[NY1972]

With NVS 2 day AUTO cell therapy, ALLO will have to target the AUTO relapsed pts. The ones that are old, frail with damages from prior therapies. A fragile population to say the least. That is why DTIL mgt not to urgent to recruit pts for sLD/19A.

[NY1972]

Tumors have too many body guards.

https://www.nature.com/articles/s41467-022-33117-y